Media

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline

Oncopeptides Partners with SD Pharma to further broaden Pepaxti reach in Spain

Precirix Announces FDA Acceptance of Investigational New Drug (IND) Application for CAM-FAP-Ac-225

Oncopeptides announces acceptance of Spanish and Italian Real-World data at IMS Annual Meeting

Gesynta Pharma Announces Second Closing of Series B Now Totaling SEK 347m – HealthCap and Hadean Growth Fund Join Strong Investor Syndicate

BONESUPPORT HOLDING AB (publ) – publishes Q2 2025 Interim report

Blended care for mental health: HelloBetter and Generali Health Solutions launch innovative care partnership

Oncopeptides announces net sales for Q2 2025

Oncopeptides’ drug Pepaxti included in European Guidelines for the treatment of multiple myeloma